Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

doi:10.1111/ejh.13604

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.

European journal of haematology - 1 May 2021

Solana-Altabella Antonio, Boluda Blanca, Rodríguez-Veiga Rebeca, Cano Isabel, Acuña-Cruz Evelyn, Blanco Albert, Marco-Ayala Javier, de la Puerta Rosalía, Díaz-González Álvaro, Piñana José L, Sanz Jaime, Sempere Amparo, Cervera José, Barragán Eva, Sargas Claudia, Ballesta-López Octavio, Megías-Vericat Juan Eduardo, Martínez-Cuadrón David, Sanz Miguel Á, Montesinos Pau

Abstract excerpt

BACKGROUND: Information regarding impact on healthcare systems of relapsed or refractory (R/R) FLT3 mutated (FLT3mut) acute myeloid leukemia (AML) is scarce. OBJECTIVE: To assess the time and reimbursement associated with hospitalizations of patients with R/R FLT3mut AML in a tertiary Spanish hospital. METHODS: Retrospective review of medical charts identified patients aged ≥ 18 years with R/R FLT3mut AML between...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to fms-Like Tyrosine Kinase 3

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Health Care Costs

Share to Hospitalization

Share to Leukemia, Myeloid, Acute

Share to Patient Acceptance of Health Care

Share to Recurrence

Share to Spain

Share to Tertiary Care Centers

Source

Open in PubMed

Identifiers

PMID: 33609315
DOI: 10.1111/ejh.13604

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence. Graph snapshot: 2026-09-29.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Healthcare resource utilization in adult patients with relapsed/refractory FLT3 mutated acute myeloid leukemia: A retrospective chart review from Spain.PMID 33609315Read ↗

Healthcare resource utilization and costs during first salvage therapy for relapsed or refractory acute myeloid leukemia in the United States.Semantic proximity Read ↗

Clinical and economic analysis of patients with acute myeloid leukemia by FLT3 status and midostaurin use at a Comprehensive Cancer Center.Semantic proximity Read ↗

Real-world treatment patterns and healthcare resource use in patients with acute myeloid leukemia in Western Europe.Semantic proximity Read ↗

Post-transplant maintenance therapy in patients with FLT3-mutated acute myeloid leukemia: Real-world treatment patterns and outcomes.Semantic proximity Read ↗

Streamline: Retrospective Cohort Study of FMS-Like Tyrosine Kinase 3-Mutated Acute Myeloid Leukemia - Real-World Treatment Patterns and Clinical Outcomes of Patients in First Relapse or Refractory Diagnosis.Semantic proximity Read ↗

A real-world, retrospective, observational study examining treatment patterns and clinical outcomes in patients with FLT3m + AML in Japan.Semantic proximity Read ↗

Allogeneic Hematopoietic Cell Transplantation in the Outpatient SettingSemantic proximity Read ↗

Real-world clinical outcomes with enasidenib in relapsed or refractory acute myeloid leukemia.Semantic proximity Read ↗

Outcomes with single-agent gilteritinib for relapsed or refractory FLT3-mutant AML after contemporary induction therapy.Semantic proximity Read ↗

Safety profile and impact on survival of tyrosine kinase inhibitors versus conventional therapy in relapse or refractory FLT3 positive acute myeloid leukemia patients.Semantic proximity Read ↗

Real-world treatment adherence and persistence of FLT3 inhibitors as post-alloHCT maintenance therapy in patients with AML in the United States: a cohort study using administrative claims data.Semantic proximity Read ↗

Upfront intensive treatment analysis of the Italian Cohort Study on FLT3-mutated AML patients (FLAM): The impact of a FLT3 inhibitor addition to standard chemotherapy in the real-life setting.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.